Valuation: Tenax Therapeutics, Inc.

Market Cap 748M 657M 611M 561M 1.05B 72.03B 1.07B 7.25B 2.83B 35.41B 2.81B 2.75B 122B P/E 2026 *
-10.4x
P/E 2027 * -10.6x
Enterprise Value 148M 130M 121M 111M 208M 14.25B 212M 1.44B 561M 7.01B 556M 544M 24.22B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-0.65%
1 week-8.17%
Current month+0.03%
1 month+12.57%
3 months+1.78%
6 months+2.28%
Current year+19.40%
1 week 14
Extreme 14
16.26
1 month 12.41
Extreme 12.41
19.4
Current year 10.25
Extreme 10.25
19.4
1 year 5.78
Extreme 5.78
19.4
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,135.04
10 years 2.77
Extreme 2.77
85,120
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 21/01/2025
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
13/7/26 Fiscal year

Chief Executive Officer

17,438 0.0657%
11/5/26 Free

Chief Financial Officer

460,000 2.6748%
11/5/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-0.65%-8.17%+138.22%-43.14% 748M
+1.07%-3.49%-3.25%+12.87% 46.35B
-0.17%+1.83%+409.33%+630.81% 40.13B
-0.17%+4.50%+9.98%+67.00% 36.33B
+0.86%+1.14%+3.88%-8.57% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.90%-2.09% - - 16.66B
+0.45%+12.77%+33.08%+145.57% 16.91B
+0.42%-5.52%+0.76%+8.50% 13.05B
-1.84%-1.50%-14.13%-30.99% 13.05B
Average +0.37%+0.62%+64.62%+90.77% 24.46B
Weighted average by Cap. +0.60%+0.76%+76.16%+136.52%

Financials

2026 *2027 *
Net sales - -
Net income -79.71M -70.01M -65.11M -59.74M -112M -7.68B -114M -773M -302M -3.77B -299M -293M -13.05B -93.97M -82.53M -76.75M -70.43M -132M -9.05B -134M -911M -356M -4.45B -353M -345M -15.38B
Net Debt -600M -527M -490M -450M -845M -57.78B -858M -5.82B -2.27B -28.41B -2.25B -2.2B -98.22B -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
25/07/26 USD 14.56 -0.58% 415,701
23/07/26 USD 14.64 -1.01% 1,400,924
22/07/26 USD 14.79 -5.92% 1,644,589
21/07/26 USD 15.72 +0.26% 1,276,799
20/07/26 USD 15.68 -1.07% 823,154
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.64USD
Average target price
35.22USD
Spread / Average Target
+140.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock